Background:A next-generation,live-attenuated yellow fever vaccine,vYF,was developed in Vero cells to improve vaccine supply and availability.The safety of and immune response to vYF as compared with those of the licen...Background:A next-generation,live-attenuated yellow fever vaccine,vYF,was developed in Vero cells to improve vaccine supply and availability.The safety of and immune response to vYF as compared with those of the licensed yellow fever vaccine,YF-VAX,are unclear.Methods:In this year 1 interim analysis of a phase 2,observer-blinded,randomized,active-controlled trial,we randomly assigned healthy adults 18 to 60 years of age in a 2:1 ratio to receive vYF or YF-VAX as a single vaccine injection on day 1.Neutralizing antibody titers were measured on day 29,month 6,and year 1.展开更多
文摘Background:A next-generation,live-attenuated yellow fever vaccine,vYF,was developed in Vero cells to improve vaccine supply and availability.The safety of and immune response to vYF as compared with those of the licensed yellow fever vaccine,YF-VAX,are unclear.Methods:In this year 1 interim analysis of a phase 2,observer-blinded,randomized,active-controlled trial,we randomly assigned healthy adults 18 to 60 years of age in a 2:1 ratio to receive vYF or YF-VAX as a single vaccine injection on day 1.Neutralizing antibody titers were measured on day 29,month 6,and year 1.
